PSMAfore: Lu-PSMA for men with castrate-resistant prostate cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 1, 2021
End Date
February 11, 2026
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 1, 2021
End Date
February 11, 2026